Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2025 | $20.00 | Buy → Neutral | H.C. Wainwright |
| 9/3/2025 | $16.00 | Equal Weight | Wells Fargo |
| 7/18/2025 | $22.00 | Buy | H.C. Wainwright |
| 2/11/2025 | $12.00 | Buy | Deutsche Bank |
| 6/12/2024 | $27.00 | Buy | Rodman & Renshaw |
| 3/5/2024 | $27.00 → $29.00 | Outperform | Oppenheimer |
| 3/5/2024 | $21.00 → $25.00 | Buy | H.C. Wainwright |
| 3/5/2024 | $20.00 → $22.00 | Buy | Needham |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE IRISH TAKEOVER RULES AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE. FOR IMMEDIATE RELEAS
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE IRISH TAKEOVER RULES AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE. FOR IMMEDIATE RELEAS
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
H.C. Wainwright downgraded Avadel Pharmaceuticals from Buy to Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Avadel Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00
H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00
DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca
– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. ("Jazz") – – Acquisition by Alkermes plc ("Alkermes") expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the third quarter ended September 30, 2025, and provided a corporate update. Pending Acq
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES — Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)— Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton— Expected to be Immediately Accretive and Enhance Profitability Upon Closing— Positions the Combined Organization to Accelerate Inn
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)